ERBB2 and breast cancer: The complexity of heterogeneity of HR-positive/HER2-positive BC impacted the outcome of patients; in fact, HR-positive/HER2-positive BC had significantly better BC-specific survival (all log-rank p < 0.001) despite HR-negative/HER2-positive BC.